|
- Corporate Presentation - Ionis Pharmaceuticals, Inc.
and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on our Form 10-K for the year ended December 31, 2023, and our most recent Form 10-Q quarterly filing, which are on file with the SEC Copies of these and other documents are available at www ionis com
- Ionis announces positive olezarsen topline results from Phase 3 study . . .
Ionis plans to file a New Drug Application in early 2024 with the U S Food and Drug Administration (FDA) in addition to EU regulatory filings If approved, olezarsen would be the first available treatment in the U S for FCS , a rare, debilitating genetic disease that can lead to acute, potentially
- Ionis and AstraZeneca Advance New Drug for NASH
announced that it has licensed IONIS-AZ6-2 5-L Rx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development IONIS-AZ6-2 5-L Rx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH) In conjunction with this
- Ionis reports second quarter 2024 financial results
Ionis' operating expenses increased in the second quarter and first half of 2024 compared to the same periods in 2023, consistent with expectations SG A expenses increased year over year primarily due to the launch of WAINUA in the U S and launch preparation activities for olezarsen and
- Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a . . .
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases
- Positive Phase 3 Data Positions Donidalorsen as a Potential Preferred . . .
This presentation includes forward-looking statements regarding Ionis’ business, financial guidance and the therapeutic and commercial potential of our commercial medicines, donidalorsen, additional medicines in development and technologies
- KEY TAKEAWAY - Ionis Pharmaceuticals, Inc.
In December 2021, Ionis launched the clinical process that the company hopes will one day deliver therapeutic benefit to people living with Angelman syndrome (AS), a rare and devastating neurodevelopmental disease
- New data presented at AD PD™2023 show IONIS-MAPT Rx (BIIB080 . . .
IONIS-MAPT Rx is an investigational antisense medicine discovered by Ionis that is being developed by Biogen It is designed to target microtubule-associated protein tau (MAPT) mRNA and prevent production of tau
|
|
|